(BUSINESS WIRE)– pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced that its financial results for the second quarter of fiscal year 2015 will be released after the market close on Thursday, February 5, 2015, followed the same day by a conference call and live webcast scheduled for 4:30 p.m. ET… Read more »
Shares of pSivida Corp closed yesterday at $3.92 . PSDV has a 1-year high of $4.94 and a 1-year low of $3.26. The stock’s 50-day moving average is $4.10 and it’s 200-day moving average is $4.21.
On the ratings front, pSivida has been the subject of a number of recent research reports. In a report issued on January 20, MLV & Co. analyst Arlinda Lee reiterated a Buy rating on PSDV, with a price target of $6.50, which reflects a potential upside of 65.8% from last closing price.
pSivida Corp develops tiny, sustained-release, drug delivery products designed to deliver drugs at a controlled and steady rate for months or years.